

DAFTAR PUSTAKA

1. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus–infected pneumonia. *N Engl J Med.* 2020;382(13):1199–207.
2. Atzrodt CL, Maknojia I, McCarthy RDP, Oldfield TM, Po J, Ta KTL, et al. A guide to COVID-19: a global pandemic caused by the novel coronavirus SARS-CoV-2. *FEBS J.* 2020;287(17):3633–50.
3. Setiawaty V, Kosasih H, Mardian Y, Ajis E, Prasetyowati EB, Siswanto, et al. The identification of first COVID-19 cluster in Indonesia. *Am J Trop Med Hyg.* 2020;103(6):2339–42.
4. WHO. WHO Coronavirus Disease (COVID-19) Dashboard [Internet]. 2021 [dikutip Mei 2021].
5. Kementrian Kesehatan RI. COVID-19 [Internet]. 2021 [dikutip September 2021].
6. Callaway BE, Cyranoski D, Mallapaty S, Stoye E, Tollefson J. Coronavirus by the numbers. *Nature.* 2020;579(1):482–3.
7. Zhou P, Yang X Lou, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature.* 2020;579(7798):270–3.
8. CDC. Symptoms of COVID-19 [Internet]. 2021 [dikutip Mei 2021].
9. PDPI, PERKI, PAPDI, PERDATIN, IDAI. Pedoman tatalaksana COVID-19 Edisi 3 Desember 2020 [Internet]. 2020 [dikutip Januari 2022].
10. Alsharif W, Qurashi A. Effectiveness of COVID-19 diagnosis and management tools: A review. *Radiography.* 2021;27(2):682–7.
11. Doi M, Author T, Crohn E, Organisation C. To Interpret the SARS-CoV-2 test, consider the cycle threshold value. *2020;1(1)10–3.*
12. Bullard J, Dust K, Funk D, Strong JE, Alexander D, Garnett L, et al. Predicting infectious SARS-CoV-2 from diagnostic samples. *Clin Infect Dis.* 2020;71(10):2663–66.
14. Kementrian Kesehatan RI. Laporan Nasional Riskesdas 2018. Jakarta: Lembaga Penerbit Badan Penelitian dan Pengembangan Kesehatan. 2019.
15. Rabaan AA, Tirupathi R, Sule AA, Aldali J, Almutair A, Alhumaid S, et al. Viral dynamics and real-time RT-PCR CT values correlation with disease severity in COVID-19. *Diagnostics.* 2021;11(6):1091.
16. Kementrian Kesehatan RI. Hipertensi. Jakarta: Pusat Data dan Informasi Kementrian Kesehatan Republik Indonesia. 2013.

17. WHO. Hypertension [Internet]. 2015 [dikutip Februari 2022].
18. Hikmawati I, Setiyabudi R. Hipertensi dan diabetes melitus sebagai penyakit penyerta utama COVID-19 di Indonesia. Pros Semin Nas Lppm Ump. 2020;1(1):95–100.
19. Drew C, Adisasmita AC. Gejala dan komorbid yang memengaruhi mortalitas pasien positif COVID-19 di Jakarta Timur, Maret-September 2020. Tarumanagara Med J. 2021;3(2):274–83.
20. Grasselli G, Greco M, Zanella A, Albano G, Antonelli M, Bellani G, et al. Risk factors associated with mortality among patients with COVID-19 in Intensive Care Units in Lombardy, Italy. JAMA Intern Med. 2020;180(10):1345–55.
21. Karyono DR, Wicaksana AL. Current prevalence, characteristics, and comorbidities of patients with COVID-19 in Indonesia. J Community Empower Heal. 2020;3(2):77.
22. Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021;19(3):141–54.
23. Samudrala PK, Kumar P, Choudhary K, Thakur N, Wadekar GS, Dayaramani R, et al. Virology, pathogenesis, diagnosis and in-line treatment of COVID-19. Eur J Pharmacol. 2020;883(1):1–12.
24. Minggu RB, Rumbajan JM, Turalaki GLA, et al. Struktur genom *Severe Acute Respiratory Syndrome Coronavirus-2* (SARS-CoV-2). J Biomedik. 2021;13(2):233–40.
25. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of Coronavirus Disease 2019 (COVID-19): A Review. J Am Med Assoc. 2020;324(8):782–93.
26. Ghinai I, McPherson TD, Hunter JC, Kirking HL, Christiansen D, Joshi K, et al. First known person-to-person transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the USA. Lancet. 2020;395(10230):1137–44.
27. Susilo A, Rumende CM, Pitoyo CW, Santoso WD, Yulianti M, Herikurniawan, et al. *Coronavirus Disease 2019: Tinjauan Literatur Terkini*. J Penyakit Dalam Indones. 2020;7(1):45.
28. Zhang R, Li Y, Zhang AL, Wang Y, Molina MJ. Identifying airborne transmission as the dominant route for the spread of COVID-19. Proc Natl Acad Sci USA. 2020;117(26):14857–63.
29. Oualha M, Bendavid M, Berteloot L, Corsia A, Lesage F, Vedrenne M, et al. Severe and fatal forms of COVID-19 in children. Arch Pediatr. 2020;27(5):235–8.

30. Wang A, Chiou J, Poirion OB, Buchanan J, Valdez MJ, Verheyden JM, et al. Single-cell multiomic profiling of human lungs reveals cell-type-specific and age-dynamic control of sars-cov2 host genes. *Elife*. 2020;9(1):1–28.
31. Xia HJ, Zhang GH, Wang RR, Zheng YT. The influence of age and sex on the cell counts of peripheral blood leukocyte subpopulations in Chinese rhesus macaques. *Cell Mol Immunol*. 2009;6(6):433–40.
32. Cook IF. Sexual dimorphism of humoral immunity with human vaccines. *Vaccine*. 2008;26(29–30):3551–5.
33. Moradi F, Enjezab B, Ghadiri-Anari A. The role of androgens in COVID-19. *Diabetes Metab Syndr Clin Res Rev*. 2020;14(6):2003–6.
34. Ko CJ, Huang CC, Lin HY, Juan CP, Lan SW, Shyu HY, et al. Androgen-induced TMPRSS2 activates matriptase and promotes extracellular matrix degradation, prostate cancer cell invasion, tumor growth, and metastasis. *Cancer Res*. 2015;75(14):2949–60.
35. Ulfa EH. Angiotensin-Converting Enzyme 2 and COVID-19: Patients, comorbidities, and therapies. *SELL J*. 2020;5(1):55.
36. Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities and its effects in coronavirus disease 2019 patients: A systematic review and meta-analysis. *Int J Infect Dis*. 2020;94(1):91–5.
37. Trougakos IP, Stamatelopoulos K, Terpos E, Tsitsilis OE, Aivalioti E, Paraskevis D, et al. Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications. *J Biomed Sci*. 2021;28(1):1–18.
38. Kumar M, Al Khodor S. Pathophysiology and treatment strategies for COVID-19. *J Transl Med*. 2020;18(1):1–9.
39. Polverino M, Polverino F, Fasolino M, Andò F, Alfieri A, De Blasio F. Anatomy and neuro-pathophysiology of the cough reflex arc. *Multidiscip Respir Med*. 2012;7(1):3–8.
40. Mesquita RR, Junior LCFS, Santana FMS, Oliveira TF, Alcantara RC, Arnozo GM, et al. Clinical manifestations of COVID-19 in the general population: systematic review. *Wien Klin Wochenschr*. 2021;133(7–8):377–82.
41. Patel KP, Patel PA, Vunnam RR. Gastrointestinal, hepatobiliary, and pancreatic manifestations of COVID-19. *J Clin Virol*. 2020;128(1):1–5.
42. Yüce M, Filiztekin E, Ozkaya KG. Biosensors and bioelectronics COVID-19 diagnosis—A review of current methods. *Biosens Bioelectron*. 2021;172(1):1–20.
43. Blanco JR, Cobos-Ceballos MJ, Navarro F, Sanjoaquin I, Revillas FAL,

- Bernal E, et al. Pulmonary long-term consequences of COVID-19 infections after hospital discharge. *Clin Microbiol Infect.* 2021;27(6):892–6.
44. Parasher A. COVID-19: Current understanding of its pathophysiology, clinical presentation and treatment. *Postgrad Med J.* 2021;97(1147):312–20.
45. Thompson BT, Chambers RC, Liu KD. Acute respiratory distress syndrome. *N Engl J Med.* 2017;377(6):562–72.
46. Meyer NJ, Christie JD. Genetic heterogeneity and risk of acute respiratory distress syndrome. *Semin Respir Crit Care Med.* 2013;34(4):459–74.
47. Mercuro NJ, Yen CF, Shim DJ, Maher TR, McCoy CM, Zimetbaum PJ, et al. Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for Coronavirus Disease 2019 (COVID-19). *JAMA Cardiol.* 2020;5(9):1036–41.
48. Tavazzi G, Pellegrini C, Maurelli M, Belliato M, Sciutti F, Bottazzi A, et al. Myocardial localization of coronavirus in COVID-19 cardiogenic shock. *Eur J Heart Fail.* 2020;22(5):911–5.
49. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. *J Thromb Haemost.* 2020;18(4):844–7.
50. Parohan M, Yaghoubi S, Seraji A, Javanbakht MH, Sarraf P, Djalali M. Risk factors for mortality in patients with Coronavirus disease 2019 (COVID-19) infection: a systematic review and meta-analysis of observational studies. *Aging Male.* 2021;23(5):1416–24.
51. Pusparini P. Tes serologi dan *Polymerase Chain Reaction* (PCR) untuk deteksi SARS-CoV-2/COVID-19. *J Biomedika dan Kesehat.* 2020;3(2):46–8.
52. Widayat W, Winarni AT, Suzery M, Ni'matullah AA, Rahmi PS. *Real Time-Polymerase Chain Reaction* (RT-PCR) sebagai alat deteksi DNA babi dalam beberapa produk non-pangan. *Indones J Halal.* 2019;2(1):26.
53. WHO. Tes Diagnostik untuk SARS-CoV-2. Pandu Interim. 2020;(1):1–19.
54. Damo NY, Porotu'o JP, Lambert GI, Rares FES. Diagnostik *Coronavirus Disease 2019* (COVID-19) dengan pemeriksaan laboratorium mikrobiologi klinik. *J e-Biomedik.* 2021;9(1):77–86.
55. Williams E, Bond K, Chong B, Giltrap D, Eaton M, Kyriakou P, et al. Implementation and evaluation of a novel real-time multiplex assay for SARS-CoV-2: in-field learnings from a clinical microbiology laboratory. *Pathology.* 2020;52(7):754–9.

56. Lai CKC, Lam W. Laboratory testing for the diagnosis of COVID-19. *Biochem Biophys Res Commun.* 2021;538(1):226–30.
57. Patel R, Babady E, Theel ES, Storch GA, Pinsky BA, George KS, et al. Report from the American Society for Microbiology COVID-19. *MBio.* 2020;11(2):1–5.
58. Gachon C, Mingam A, Charrier B. Real-time PCR: What relevance to plant studies?. *J Exp Bot.* 2004;55(402):1445–54.
59. Rao SN, Manissero D, Steele VR, Pareja J. A narrative systematic review of the clinical utility of cycle threshold values in the context of COVID-19. *Infect Dis Ther.* 2020;9(3):573–86.
60. Candrawati NW, Cassidy WR. Interpretasi nilai *Cycle Threshold* (CT) *Reverse Transcriptase-Polymerase Chain Reaction* (RT-PCR) SARS-CoV-2 pada pasien hamil dengan uji antibodi SARS-CoV-2 positif dan COVID-19 asimtomatis. *I Sains Medis.* 2021;12(3):822–7.
61. PAMKI. Arti Klinis Nilai CT [Internet]. 2020 [dikutip Januari 2022].
62. Rhee C, Kanjilal S, Baker M Klompas M. Duration of SARS-CoV-2 infectivity: When is it safe to discontinue isolation?. *Clin Infect Dis.* 2021;72(8):1467–74.
63. Gniatzowski V, Morris CP, Wohl S, Mehoke T, Ramakrishnan S, Thielen P, et al. Repeat COVID-19 molecular testing: Correlation of SARS-CoV-2 culture with molecular assays and cycle thresholds. *Clin Infect Dis.* 2021;73(4):e860–69.
64. Tonglolangi OS, Pratiningrum M, Yadi Y. Hubungan nilai CT pada pemeriksaan *Real-Time RT-PCR* SARS-CoV-2 dengan gejala klinis. *J Kedokt Mulawarman.* 2021;8(3):89.
65. Zhou R, Li F, Chen F, Liu H, Zheng J, Lei C, et al. Viral dynamics in asymptomatic patients with COVID-19. *Int J Infect Dis.* 2020;96(1):288–90.
67. Bordon J. The importance of cycle threshold values in the evaluation of patients with persistent positive PCR for SARS-CoV-2: Case study and brief review. *J Respir Infect.* 2020;4(1):2–6.
68. Liu Y, Yan LM, Wan L, Xiang TX, Le A, Liu JM, et al. Viral dynamics in mild and severe cases of COVID-19. *Lancet Infect Dis.* 2020;20(6):656–7.
69. NCBI. Real-Time qRT-PCR [Internet]. 2021 [dikutip Desember 2021].
70. Long QX, Tang XJ, Shi QL, Li Q, Deng HJ, Yuan J, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. *Nat Med.* 2020;26(8):1200–4.
71. Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA,

- et al. Virological assessment of hospitalized patients with COVID-2019. *Nature*. 2020;581(7809):465–9.
72. Sundari L, Bangsawan M. Faktor-faktor yang berhubungan dengan kejadian hipertensi. *J Ilm Keperawatan Sai Betik*. 2015;11(2):216–23.
73. Perhimpunan Dokter Hipertensi Indonesia. Konsensus Penatalaksanaan Hipertensi 2019. Jakarta: Perhimpunan Dokter Hipertensi Indonesia. 2019.
74. Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. *Circ Res*. 2000;87(5):e1–9.
75. Liu Y, Yang Y, Zhang C, Huang F, Wang F, Yuan J, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. *China Life Sci*. 2020;63(3):364–74.
76. Verdecchia P, Cavallini C, Spanevello A, Angeli F. COVID-19 : ACE2centric infective disease ?. *Hypertension*. 2020;76(2):294–9.
77. Tadic M, Cuspidi C, Grassi G, Mancia G. COVID-19 and arterial hypertension : Hypothesis or evidence?. *J Clin Hypertens (Greenwich)*. 2020;22(7):1120–6.
78. Menteri Kesehatan Republik Indonesia. Rencana aksi nasional kesehatan lanjut usia tahun 2016-2019 [Internet]. 2016 [dikutip Maret 2022].
79. Listiana D, Effendi S, Saputra YE. Faktor-faktor yang berhubungan dengan kepatuhan penderita hipertensi dalam menjalani pengobatan di Puskesmas Karang Dapo Kabupaten Muratara. *J Nurs Public Heal*. 2020;8(1):11–22
80. Azwar MK, Setiati S, Rizka A, Fitriana I, Saldi SRF, Safitri ED. Clinical profile of elderly patients with COVID-19 hospitalised in Indonesia's national general hospital. *Acta Med Indones*. 2020;52(3):199–205.
81. Qiu P, Zhou Y, Wang F, Wang H, Zhang M, Pan X, et al. Clinical characteristics, laboratory outcome characteristics, comorbidities, and complications of related COVID-19 deceased: a systematic review and meta-analysis. *Aging Clin Exp Res*. 2020;32(9):1869–78.
82. Sanyaolu A, Okorie C, Marinkovic A, Patidar R, Younis K, Desai P, et al. Comorbidity and its impact on patients with COVID-19. *SN Compr Clin Med*. 2020;2(8):1069–76.
83. Miura K, Nagai M, Ohkubo T. Epidemiology of hypertension in Japan: Where are we now?. *Circ J*. 2013;77(9):2226–31.
84. Riniasih Wahyu F. Gambaran tekanan darah pada lansia dengan hipertensi yang mengkonsumsi daun kelor di Puskesmas Kradenan 1 Kabupaten Grobogan. *J TSCNers*. 2021;6(2):42–7.

85. Gayo R, Lubis SA. Gambaran faktor risiko hipertensi berdasarkan derajat hipertensi di Puskesmas Medan Johor tahun 2015. Ibnu Nafis. 2017;6(1):47–54.
86. Nurhidayati I, Aniswari AY, Sulistyowati AD, Sutaryono S. Penderita hipertensi dewasa lebih patuh daripada lansia dalam minum obat penurun tekanan darah. J Kesehat Masy Indones. 2018;13(2):4–8.
87. Wardani, Ahmad M. Gambaran faktor risiko hipertensi berdasarkan derajat hipertensi. Media Kesehat Politek Kesehat Makassar. 2021;16(2):245–53.
88. Suciana F, Agustina NW, Zakiyatul M. Korelasi lama menderita hipertensi dengan tingkat kecemasan penderita hipertensi. J Keperawatan dan Kesehat Masy Cendekia Utama. 2020;9(2):146.
89. Rahmayanti Y. Hubungan lama menderita hipertensi dengan penurunan fungsi kognitif pada lansia. J Aceh Med. 2018;2(2):241–6.
90. Putra IMAA. Hubungan komorbiditas terhadap derajat keparahan admisi dan *outcome* pasien COVID-19 di Rumah Sakit Bethesda Yogyakarta (skripsi). Yogyakarta: Fakultas Farmasi Universitas Sanata Dharma. 2021. p. 18.
91. Khedr EM, Daef E, Mohamed-Hussein A, Mostafa EF, Zein M, Hassany SM, et al. Impact of comorbidities on COVID-19 outcome. medRxiv Prepr Serv Heal Sci. 2020;1(1):1–26.
92. Alkautsar A. Hubungan penyakit komorbid dengan tingkat keparahan pasien Covid-19. J Med Hutama. 2021;3(1):402–6.
93. Choudhuri J, Carter J, Nelson R, Skalina K, Osterbur-Badhey M, Johnston A, et al. SARS-CoV-2 PCR cycle threshold at hospital admission associated with patient mortality. PLoS One. 2020;15(1):1–14.
94. Dergaa I, Abubaker M, Souissi A, Mohammed AR, Varma A, Musa S, et al. Age and clinical signs as predictors of COVID-19 symptoms and cycle threshold value. Libyan J Med. 2022;17(1):1–10.
95. Gulbudak H, Karvar S, Soydan G, Ulger ST, Kandemir O, Tamer L, et al. Comparison of real time pcr cycle threshold values in symptomatic and asymptomatic covid-19 patients. Mikrobiyol Bul. 2021;55(3):435–44.
96. Manurung JJ, Sukohar A. Hubungan antara *CT Value* pada *test* RT-PCR terhadap parameter klinis pasien COVID-19. 2021;11(1):119–24.
97. Jubhar C, Mangimbulude, Tandaan I, Lumintang V, Akualing JS, Makawimbang A, et al. Analisa potensi penularan COVID-19 pada tenaga kesehatan RSUD Tobelo terkonfirmasi berdasarkan nilai *Cycle Threshold* (CT). 2021;17(1):267–74.
98. Pasculli P, Zingaropoli MA, Masci GM, Mazzuti L, Perri V, Paribeni F, et al. Chest computed tomography score, cycle threshold values and

- secondary infection in predicting COVID-19 mortality. *New Microbiol.* 2021;44(3):145–54.
99. Shi F, Wu T, Zhu X, Ge Y, Zeng X, Chi Y, et al. Association of viral load with serum biomarkers among COVID-19 cases. *Virology.* 2020;546(1):122–6.
100. Garg K, Sharma K, Gupta A, Chopra V. Association of cycle threshold values of CBNAAT with severity and outcome in COVID-19. *Monaldi Arch chest Dis.* 2021;91(4):1–5.
101. Magleby R, Westblade LF, Trzebucki A, Simon MS, Rajan M, Park J, et al. Impact of severe acute respiratory syndrome coronavirus 2 viral load on risk of intubation and mortality among hospitalized patients with coronavirus disease 2019. *Clin Infect Dis.* 2021;73(11):E4197–205.
102. Fajnzylber J, Regan J, Coxen K, Corry H, Wong C, Rosenthal A, et al. SARS-CoV-2 viral load is associated with increased disease severity and mortality. *Nat Commun.* 2020;11(1):1–9.
103. Júnior JVJS, Merchioratto I, de Oliveira PSB, Lopes TRR, Brites PC, de Oliveira EM, et al. End-point RT-PCR: A potential alternative for diagnosing coronavirus disease 2019 (COVID-19). *J Virol Methods.* 2021;288(1):2020–2